In a series of 28 metastatic colorectal patients treated with gefitinib monotherapy, biologic evaluation of total and activated EGR, activated AKT, MAP-kinase and Ki 67 on paired pre- and 1 week post- treatment tumour samples could not confirm a gefitinib-induced decreased expression of these molecular markers [17]. This evidence concerns the gene AKT1 and neoplasm.